Marc beer is an entrepreneur with experience in pharmaceutical, Biotechnology and diagnostic markets. He holds a bachelor of science from the Miami University in Ohio. He is also the co-founder of Renovia group. He serves as a member of the Notre Dame Research and commercialization advisory board. He is also a member of the Miami University Business Advisory Council and the University’s Graduate Studies Research and Advisory committee.
His excellent leadership qualities and innovations enable him to practice business deals that assist people as he is committed to excelling in these businesses. He has created jobs to more than 300 people. He has guided companies that have since been listed in NASDAQ as well as going public.
Just recently Marc Beer was appointed as the chairman of the LumeNXT board. LumeNXT is a private company doing business with the aim of developing proprietary surgical lighting artifacts for simple persistent surgeries. He has over twenty-five years of experience in this industry thus suited for the new appointment as a chairman. LumeNXT boasts of engineers and surgeons that are experienced in the area of surgical illumination. Illumination increases precision, visibility, and flexibility during the surgical operation thus making the innovation helpful in comparison to customary techniques.
The technology offers a platform where illumination is used as a temperature reduction method to enhance surgical accuracy at an affordable cost and ensuring there is enough safety. Marc Beer is tasked with the duty of guiding the LumeNXT Company into positive growth and leading it to worldwide commercial rollout. His also tasked to make sure the company goes into big profits as it grows steadily.
LumeNXT original outlook protects tissues against damage to any high temperatures by incessantly eradicating the heat from the light giving elements. This technology has been of great help to the surgeons as it is more efficient. The company is dedicated to coming up with modified and individualized solutions that are based on values that the customer upholds.
He has also been at the helm of Minerva Neurosciences Company as the chairman of the board. It is a biopharmaceutical company developing products that treat diseases associated with the central nervous system. Before joining Minerva he held positions in the biopharmaceutical industry where he was tasked with launches which were commercial in nature looking into rare diseases in the world, worldwide growth, acquisitions, and IPOs.
Some of Marc Beer such position as a top executive includes the board o Good Start Genetics as its founding chairman, The CEO of Aegerion Pharmaceuticals, CEO of ViaCell, Vice President of Global Marketing at Genzyme as well as the Biotechnology Industry Organization Governing committee. Learn more: https://www.businesswire.com/news/home/20180821005199/en/Renovia-Completes-42.3-Million-Series-Financing
Nitin Khanna seeks to bolster the small business atmosphere of Portland, Oregon. The former co-founder of Saber Corp, which sold for $420 million in 2007 to Electronic Data Systems, is now the Chief Executive Officer (CEO) of MergerTech.
MergerTech is an investment firm that specializes in mergers and acquisitions of technology companies with a valuation of between $10 million and $200 million. To put it simply, MergerTech matches sellers with buyers across a global network of technology companies.
Nitin Khanna began the company with his brother and Chief Operations Officer (COO), Karan Khanna, after spinning the company off from Martin Wolf Securities, which was previously simply a subsidiary. Recognizing the unique niche to fill, Nitin Khanna has been extremely successful in its short existence, matching seven sellers with buyers in its first seven months of independent operation. This is further elaborated in this link.
According to Nitin Khanna, MergerTech’s success begins with its people. MergerTech thrives from hiring highly qualified and competent persons to manage and perform the different aspects of MergerTech’s complex business. Because MergerTech signs the majority of potential clients to contracts, for their merger or acquisition, Nitin Khanna likes to know the right people are handling the job beyond his initial duties.
Nitin Khanna is not only a successful businessman, but a supporter of the Portland Oregon business community. MergerTech is a testament to that. The goal of MergerTech is to bolster the business community by attracting, first, angel investors and then, second, venture capitalists. If MergerTech can bring more investment to the community through mergers and acquisitions, then angel investors and venture capitalists are likely to follow. You can find out more about the new ventures of this successful business man here https://medium.com/@NitinKhannaCeo/nitin-khanna-riding-the-cannabis-wave-with-cura-cannabis-solutions-9fcf612ee529
According to Nitin Khanna, Angel investors must come first in any investment. A regular supply of wealthy individuals seeking to invest in Portland startups precedes larger venture capitalist firms, which could bring greater prosperity to the community.
Follow Nitin on Twitter.
The chairman, CEO, and co-founder of Renovia Inc. has obtained a total of $32 million in a Series B round and a further $10 million for his medical technology startup venture debt. His leadership in this organization is attributed to his experience in the development and commercialization of enterprises in biotechnology and pharmaceutical devices, and diagnostics Marc Beer focuses on developing products that diagnose and treat urinary incontinence, which is a pelvic floor disorder with a potential to affect more than 250 million women.
Leaders in innovation
The FDA approved Leva in April, which is Renovia’s first product. The obtained funding included the participation of the Longwood Fund. This group deals with the healthcare issues that supported Renovia is early in the funding. Perceptive Adviser of New York and Ascension Ventures of Missouri funded the Series B Round. The funding will assist the development and testing of four products for Renovia. Marc Beer intends to come up with a new generation of Leva.
Marc Beer appreciates the funding and says it is an opportunity to share a vision for better diagnosis and treatment for women facing pelvic floor disorders. He hopes to lead the development of the company into combining its innovative and proprietary sensor technologies with digital health platform. The combination of digital health platforms with technological advancements will provide the customers with valuable data and will produce new options for treatment
Marc Beer opines that if there is an increased understanding of the pelvic floor disorder, there is a chance to lower the long-term health care costs.
Marc Beer’s style of dynamic leadership demonstrates his ability to provide workable solutions that satisfy urgent issues. Together with Ramon Iglesias and Yolanda Lorie, they cofounded Renovia in 2016. His energy and vision make his style of leadership ready to take on ventures that benefit their customers. Marc sees a need for a company that addresses urgent issues, which is a reason why he decided to create Renovia.
His interest in the pharmaceutical field focused on sales and marketing, and this was before he went to work at Genzyme. Marc desires to give back to the society, which is why he was at the Mass Life Science Board for the Commonwealth of Massachusetts.
About Marc Beer
Marc Beer is the co-founder, Chief Executive Officer, and chairman of Renovia Inc. he attended Miami University to study a Bachelor of Science in Business and graduated in 1987. Marc has excellent leadership skills in business as well as public areas of responsibility. He worked at OvaScience as a Strategic Consultant. He is also a member of the Joe Andruzzi Cancer Foundation, which provides financial aid to alleviate the economic and emotional stress experienced by cancer patients and their families. Marc Beer is a member of the Miami University Business Advisory Council. Learn more: https://renoviainc.com/